Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech that has proved helpful conscientiously but unsuccessfully to create an one-time therapy, variously referred to as Pro 140, leronlimab, and Vyrologix.

In development of this particular therapy, CytoDyn has cast its net wide and far both geographically and in terminology of prospective indications.

CytoDyn’s inventories of leronlimab are building up, whether they’ll actually be being used is an open question.

While CYDY  is actually dawdling, promote opportunities for leronlimab as being a combination therapy in the therapy of multi-drug-resistant HIV happen to be closing.

I’m writing my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale of my last few shares. My first CytoDyn article, “CytoDyn: What to be able to Do When It’s Too Good In order to Be True?”, set away the following prediction:

Instead I expect it to be a serial disappointer. CEO Pourhassan offered such a very promotional image in the Uptick Newswire employment interview which I came away with a bad opinion of the company.

Irony of irony, my poor viewpoint of the business enterprise has grown steadily, however, the disappointment hasn’t been financial. Two years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades during $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is it that delivers a > six bagger yet still disappoints? Therein sits the story; let me explain.

CytoDyn acquired its much-storied therapy (which I shall refer to as leronlimab) back in 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor for your treatment as well as avoidance of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical growth mAb with demonstrated anti-viral activity of HIV infected subjects. Today’s transaction of $3.5 million transfers ownership of this expertise as well as linked intellectual property from Progenics to CytoDyn, and roughly twenty five million mg of bulk drug substance…. milestone payments after commencement of a level III clinical trial ($1.5 million) along with the very first new drug application endorsement ($five million), as well as royalty payments of 5 percent of net sales after commercialization.

Since that moment, CytoDyn’s leading nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition into a springboard for CytoDyn to get a market cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with numerous therapies and numerous indications, it’s this individual treatment as well as a “broad pipeline of indications” since it places it. I call such pipelines, “pipedots.” In CytoDyn’s case it touts the leronlimab of its as a likely beneficial therapy of dozens of indications.

Its opening banner on its website (below) shows an active company with diverse interests albeit centered on leronlimab, multiple illness types, multiple publications in addition to multiple presentations.

Can it all be smoke and mirrors? That is a question I have been asking myself through the very start of my interest in this business. Judging by the multiples of a huge number of several responses on listings accessible via Seeking Alpha’s CytoDyn Summary webpage, I am a lot from alone in this question.

CytoDyn is a traditional battleground, or maybe some could say cult stock. Its adherents are fiercely shielding of the prospects of its, quick to label some bad opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *